MedTrace Logo

Dose-finding Study of Moxidectin for Treatment of Scabies

NCT03905265 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-09-22

Study results available
· View outcomes & findings →

Summary

The effective dose of moxidectin to treat human scabies is not known. This study aims to provide proof of concept that a single dose of moxidectin is effective in eliminating the scabies parasite in humans and to enable the determination of an optimal dose of moxidectin for treatment of scabies for further clinical studies.

Conditions

  • Scabies

Interventions

DRUG

Moxidectin Oral Product

The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required

Sponsors & Collaborators

  • Medicines Development for Global Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-13
Primary Completion
2022-02-28
Completion
2022-02-28
FDA Drug
Yes

Countries

  • Australia
  • Austria
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03905265 on ClinicalTrials.gov